https://journals.lww.com/americantherapeutics/fulltext/2021/...
I think though that most people aren't asking the right question about ivermectin. From a population health standpoint it's clearly not a viable alternative to vaccination (and I encourage everyone to get vaccinated if they can). But vaccination isn't 100% effective so there will continue to be many symptomatic breakthrough cases. So the real question is whether ivermectin should be added to the treatment protocol along with other drugs including monoclonal antibodies? Is it clinically justified on a risk / reward basis?
https://www.covid19treatmentguidelines.nih.gov/about-the-gui...
The NIH is currently sponsoring a large scale clinical trial of ivermectin and other drugs.
https://www.nih.gov/research-training/medical-research-initi...
While waiting for results from that study does it make sense to act based on lower quality research? There are at least some small studies which appear to show a significant clinical benefit with minimal risk.
https://www.mdpi.com/1999-4915/13/6/989
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5...
https://journals.sagepub.com/doi/10.1177/03000605211013550
It's unfortunate that the issue has been so heavily politicized. Decisions on off-label drug use should generally be left up to individual physicians.